radiolabeled MMP inhibitors; iodine-123; in vivo biodistribution; SPECT; tumor imaging
Abstract :
[en] Aim: As a part of our efforts to use small organic matrix metalloproteinase (MMP) inhibitors with improved characteristics for the diagnosis and treatment of different kinds of tumor tissues, biphenylsulfonamide analogues were synthesized. This study reports on the in vivo biodistribution of iodine-123-labeled biphenylsulfonide and analogues in A549 lung carcinoma inoculated into athymic mice and the evaluation of their suitability as imaging agents using a single photon emission computed tomography (SPECT) camera. Methods: The radioiodinated carboxylic and hydroxamic MMP inhibitors 2-(4′- [123I]iodobiphenyl-4-sulfonylamino)-3-(1H-indol-3-yl)-propionic acid (1′) and 2-(4′-[123I]iodobiphenyl-4- sulfonylamino)-3-(1H-indol-3-yl)-propionamide (2′) were synthesized by electrophilic aromatic substitution of the tributylstannyl derivatives. Planar gamma camera imaging was performed in nu/nu athymic mice bearing an A549 tumor using a Toshiba GCA-9300A/hg SPECT camera in planar mode equipped with a high-resolution, parallel-hole collimator. Results: Radiosynthesis of (1′) and (2′) resulted in radiochemical yields of 60 ± 5% (n ± 3) and 70 ± 5% (n = 6), respectively. Evaluation of tumors induced in athymic mice by the inoculation of non-small cell lung A549 carcinoma cells, showed a tumor uptake of 0.27–0.01 percent injected dose per gram (%ID/g) (3 hours–48 hours p.i.), a tumor-blood ratio of 0.7, a tumor-muscle ratio of 1.6, and a tumor-fat ratio of 0.5 at 24 hours (p.i.) for compound 1′. For compound 2′ a tumor uptake of 0.7–0.04 %ID/g (3 hours–48 hours p.i.), a postinjection tumor-blood ratio of 1.2, a tumor-muscle ratio of 3.2, and a tumor-fat ratio of 2.4 at 48 hours p.i. was observed. SPECT evaluation confirmed the results obtained from biodistribution. Conclusion: In vivo evaluation of these radioiodinated carboxylic and hydroxamic MMP inhibitor tracers revealed that they do not appear suitable as tumor-imaging agents.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Oltenfreiter, R.
Staelens, L.
Labied, Soraya ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Kersemans, V.
Frankenne, F.
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Van de Wiele, C.
Slegers, G.
Language :
English
Title :
Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents
Publication date :
2005
Journal title :
Cancer Biotherapy and Radiopharmaceuticals
ISSN :
1084-9785
eISSN :
1557-8852
Publisher :
Mary Ann Liebert, Inc., New Rochelle, United States - New York
Egebled M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161.
Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: Innovations for the posttrial era. Nat Rev Cancer 2002;2:657.
Folgueras AR, Pendás AM, Sánchez LM, et al. Matrix metalloproteinases in cancer: From new functions to new inhibition strategies. In J Dev Biol 2004;48:411.
Sounni NE, Noel A. Membrane-type matrix metalloproteinases and tumor progression. Biochimie 2005;87:329.
Hiraoka N, Allen E, Apel IJ, et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998;94:365.
Liotta LA, Tryggvaason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67.
Shima I, Sasaguri Y, Kusukawa J, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer 1992;20:2747.
Tokuraku M, Sato S, Murakami S, et al. Activation of the precursor of gelatinase A/72 kDEa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995;64:355.
Talyensaari-Mattila A, Paakko P, Hoyhtya M, et al. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153.
Sier CF, Kubben KJ, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413.
Whittaker M, Floyd CD, Brown P, et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735.
Broadhurst MJ, Brown PA, Lawton G, et al. Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg Med Chem Lett 1997;7:2299.
Morphy JR, Millican TA, Porter JR. Matrix metalloproteinase inhibitors: Current status. Curr Med Chem 1995;2:743.
Oltenfreiter R, Staelens L, Lejeune A, et al. New radioiodinated carboxylic and hydroxamic MMP inhibitor tracers as potential tumor-imaging agents. Nucl Med Biol 2004;31:459.
O'Brien PM, Ortwine DF, Pavlovsky AG, et al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem 2000;43:156.
Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) type IV collagenaes in colorectal cancer. Cancer Res 1996;56:190.
Hajitou A, Baramova EN, Bajou K, et al. FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells. Oncogene 1998;17:2059.
Maquoi E, Sounni NE, Devy L, et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, and orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 2004;10:4038.
Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod 2003;69:976.
Remacle A, McCarthy K, Noël A, Maguire T, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89(2):118.
Fabunmi RP, Baker AH, Murray EJ, et al. Divergent regulation by growth factors and cytokines of 95 and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J 1996;315:335.
McCawley LJ, Matrisian LM. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today 2000;6:149.
Zheng QH, Fei X, Liu X, et al. Comparative studies of potential cancer biomarkers carbon-11-labeled MMP inhibitors (S)-2-4′-[11C]methoxybiphenyl- 4-sulfonyl-amino)-3-methylbutyric acid and N-hydroxy-(R)-2[[4′-[11C] methoxyphenyl)sulfonyl]benzylamino]-3-methyl-butanamide. Nucl Med Biol 2004;31:77.
Zheng QH, Fei X, DeGrado TR, et al. Synthesis, biodistribution, and micro-PET imaging of a potential cancer biomarker carbon-11-labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbuty ric acid [11C]methyl ester. Nucl Med Biol 2003;30:753.
Furumoto S, Takashima K, Kubota K, et al. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003;30:119.
